RemeGen Co Documents
Documents
0
Ticker
688331.SS
ISIN
CNE100005B03
RemeGen Co SEC Filings
Type | Report | Date |
|---|---|---|
| No documents available | ||
RemeGen Co Documents 2026
This page contains all official documents and SEC filings for RemeGen Co stock (688331.SS, ISIN: CNE100005B03). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 0 documents are available. Data is updated regularly to provide investors with a complete overview of RemeGen Co's regulatory filings.
RemeGen Co Stock analysis
RemeGen Co RemeGen Co Ltd generates revenue by researching, developing, and manufacturing innovative biopharmaceuticals, specifically focusing on therapeutic antibody drugs. The company's product portfolio includes tetacept (RC18), veldicitumab (RC48), and a dual-target fusion protein (RC28). These products are designed to treat major diseases such as oncology, autoimmune diseases, and ophthalmology. The firm operates primarily in the domestic market within China, where it commercializes its discoveries. Its business model relies on the development of various antibody types, including antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies. This focus allows the company to address significant medical needs through its specialized therapeutic offerings.